These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23912993)

  • 21. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent and selective inhibition of gene expression by an antisense heptanucleotide.
    Wagner RW; Matteucci MD; Grant D; Huang T; Froehler BC
    Nat Biotechnol; 1996 Jul; 14(7):840-4. PubMed ID: 9631007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides.
    Hori S; Yamamoto T; Obika S
    Biochem Biophys Res Commun; 2015 Aug; 464(2):506-11. PubMed ID: 26159921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing the sequence-specificity of antisense oligonucleotides in drug discovery.
    Hagedorn PH; Hansen BR; Koch T; Lindow M
    Nucleic Acids Res; 2017 Mar; 45(5):2262-2282. PubMed ID: 28426096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to antisense oligonucleotides by application of secondary structure predictions and RNase H in combination with MALDI-TOF mass spectrometry.
    Gabler A; Krebs S; Seichter D; Förster M
    Nucleic Acids Res; 2003 Aug; 31(15):e79. PubMed ID: 12888531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.
    Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F
    Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
    Zhou T; Kim Y; MacLeod AR
    Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining the factors that contribute to on-target specificity of antisense oligonucleotides.
    Lima WF; Vickers TA; Nichols J; Li C; Crooke ST
    PLoS One; 2014; 9(7):e101752. PubMed ID: 25072142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in therapeutic bacterial antisense biotechnology.
    Hegarty JP; Stewart DB
    Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview on AON design.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():117-29. PubMed ID: 22454058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense oligonucleotides: from design to therapeutic application.
    Chan JH; Lim S; Wong WS
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
    Henry SP; Marcusson EG; Vincent TM; Dean NM
    Trends Pharmacol Sci; 2004 Oct; 25(10):523-7. PubMed ID: 15380936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.
    Weidner DA; Busch H
    Oncol Res; 1994; 6(6):237-42. PubMed ID: 7865899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.
    Iwamoto N; Butler DCD; Svrzikapa N; Mohapatra S; Zlatev I; Sah DWY; Meena ; Standley SM; Lu G; Apponi LH; Frank-Kamenetsky M; Zhang JJ; Vargeese C; Verdine GL
    Nat Biotechnol; 2017 Sep; 35(9):845-851. PubMed ID: 28829437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical and clinical pharmacology of antisense oligonucleotides.
    Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
    Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
    Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
    Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binary Antisense Oligonucleotide Agent for Cancer Marker-Dependent Degradation of Targeted RNA.
    Drozd VS; Eldeeb AA; Kolpashchikov DM; Nedorezova DD
    Nucleic Acid Ther; 2022 Oct; 32(5):412-420. PubMed ID: 35852843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense oligonucleotides as therapeutics for hyperlipidaemias.
    Crooke RM
    Expert Opin Biol Ther; 2005 Jul; 5(7):907-17. PubMed ID: 16018737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective binding of trisamine-modified phosphorothioate antisense DNA to target mRNA improves antisense activity and reduces toxicity.
    Matsukura M; Okamoto T; Miike T; Sawai H; Shinozuka K
    Biochem Biophys Res Commun; 2002 May; 293(5):1341-7. PubMed ID: 12054660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.